8-K
filed March 2, 2023, 6:59 PM ET
ticker NPCE
CIK 0001528287
earnings
confidence high
sentiment negative
materiality 0.70
NeuroPace Q4 revenue $12.8M (+16% YoY); guides FY2023 revenue $50-52M
NeuroPace Inc
- Q4 2022 revenue $12.8M (+16% YoY); initial implant revenue $9.8M (+15% YoY).
- Full year 2022 revenue $45.5M (+1% YoY); net loss $47.1M vs $36.1M in 2021.
- FY2023 guidance: revenue $50-52M (10-14% growth), gross margin 69-71%, op expenses $75-77M.
- DIXI Medical distribution contributed $1.6M in Q4; NAUTILUS study for primary generalized epilepsy ongoing.
- Cash burn reduced to ~$15M in H2 2022 from ~$23M in H1; cash $77.4M at year-end.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc updated its Full Year 2023 guidance (initiated).
- Period
- Full Year 2023
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Full Year 2023 Financial Guidance • Total revenue to range between $50.0 million to $52.0 million, growing approximately 10% to 14% over 2022 • Gross margin to range between 69% to 71% • Total operating expenses to range between $75.0 million to $77.0 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
- Period
- the full year ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
- Period
- the full year ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
Total revenue was $45.5 million in 2022, representing growth of 1% compared to 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the full year ended December 31, 2022 results: EPS not provided.
- Period
- the full year ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
Net loss was $47.1 million for 2022, compared to a net loss of $36.1 million in 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
- Period
- the fourth quarter ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
On March 2, 2023, NeuroPace, Inc. issued a press release announcing its financial results for the fiscal quarter and full year ended December 31, 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
- Period
- the fourth quarter ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
Total revenue was $12.8 million in the fourth quarter of 2022, representing growth of 16% compared to the prior year period and 15% compared to the prior quarter.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
NeuroPace Inc reported the fourth quarter ended December 31, 2022 results: EPS not provided.
- Period
- the fourth quarter ended December 31, 2022
- EPS
- not provided
- Result
- reported results
Exact text from the filing
Net loss was $11.1 million for the fourth quarter of 2022, compared to a net loss of $10.7 million in the prior year period.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.